Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis

Published:2016-10-20 Issue:1 Volume:2 Page:
ISSN:2059-1381
Container-title:Renal Replacement Therapy
language:en
Short-container-title:Ren Replace Ther

Author:

Oyama Satoko,Hirose Chihiro,Hori Kenichiro,Sugano Katsuhiro,Zhang Jie,Tamura Miyuki,Tomita Kimio

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1186/s41100-016-0068-5.pdf

Reference19 articles.

1. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982;668:49–59.

2. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10(6):403–9.

3. Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650–4.

4. Sakata K, Hashimoto T, Ueshima H, Okayama A, NIPPON DATA 80 Research Group. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol. 2001;17(5):461–8.

5. Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY. Serum uric acid levels show a ‘J-shaped’ association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2004;19(2):457–62.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joint Deep-Learning-Enabled Impact of Holistic Care on Line Coagulation in Hemodialysis;Journal of Healthcare Engineering;2021-12-16

2. Development and validation for the quantitative determination of xanthine oxidoreductase inhibitor topiroxostat by LC-MS/MS and its clinico-pharmacokinetic study;Journal of Pharmaceutical and Biomedical Analysis;2020-09

3. Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model;Biomedicine & Pharmacotherapy;2020-01

4. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients;Biological & Pharmaceutical Bulletin;2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3